Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 19, Issue 4, 1997, Pages 231-239

  Desai, Pankaj B ^a,b   Duan, John ^a   Sridhar, Rajagopatan ^c   Damle, Bharat D ^a,d  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c HOWARD UNIVERSITY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

B16 murine melanoma; B16V cells; B16VDXR cells; Dipyridamole; Doxorubicin; Multidrug resistance; P glycoprotein; Reversal of drug resistance

Indexed keywords

DIPYRIDAMOLE; DOXORUBICIN; GLYCOPROTEIN P;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CYTOTOXICITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MELANOMA CELL; MULTIDRUG RESISTANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION INHIBITORS;

EID: 0030742762     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Beck, W.T. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 1990, 17(Suppl. A): 11-20.
2. Endicott, J.A., Ling, V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 1989, 58: 137-71.
3. Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., Pastan, I. Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84: 265-9.
4. Ford, J., Hait, W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42: 155-98.
5. Grem, J.L., Fischer, P.H. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther 1989, 40: 349-71.
6. Asoh, K.I., Saburi, Y., Sato, S.I., Nagoe, I., Kohno, K., Kuwano, M. Potentiation of some anti-cancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines. Jpn J Cancer Res 1989, 80: 475-81.
7. Shalinsky, D., Slovak, M., Howell, S. Modulation of vinblastine sensitivity by dipyridamole in multidrug-resistant fibrosarcoma cells lacking mdrl expression. Br J Cancer 1991, 64: 705-9.
8. Damle, B.D., Sridhar, R., Desai, P.B. Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells. Int J Cancer 1994, 56: 113-8.
9. Weenen, H., Osterop, A., Van der Poort, S., Lankelma, J., Van der Vijgh, W., Pinedo, H. Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. J Pharm Sci 1986, 75: 1201-4.
10. Geran, R., Greenberg, N., MacDonald, M., Schumacher, A., Abott, B. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972, 3: 1-103.
11. Formelli, F., Carsana, R., Pollini, C. Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice. Cancer Chemother Pharmacol 1986, 16: 15-21.
12. Chan, T.C., Howell, S.B. Mechanism of synergy between N-phosphonoacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line. Cancer Res 1985, 45(8): 3598-604.
13. 3H]-thymidine in the rat. Biochem Pharmacol 1986, 35 (2): 3871-7.
14. MacGregor, T.R., Sardi, E.D. in vitro protein binding behavior of dipyridamole. J Pharm Sci 1991, 80(2): 119-20.